Here are the S-3 shelf registrations from Tyra Biosciences, Inc. (TYRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.
Tyra Biosciences, Inc. (TYRA) has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer and sell, from time to time after effectiveness, common stock, preferred stock, debt securities, warrants and units in one or more future offerings. Specific terms, amounts and prices for each issuance will be detailed in accompanying prospectus supplements.
Tyra is a clinical-stage biotechnology company focused on precision medicines targeting FGFR biology, built on its in-house SNÅP drug-design platform. Its lead oral candidate, dabogratinib, is in development for multiple urothelial and bladder cancer indications and achondroplasia, alongside additional FGFR-focused programs TYRA-430 and TYRA-200 in liver and cholangiocarcinoma studies.
As of June 30, 2026, Tyra’s authorized capital stock consisted of 500,000,000 shares of common stock and 50,000,000 shares of preferred stock. Its common stock trades on the Nasdaq Global Select Market under the symbol TYRA, with a last reported sale price of $22.03 per share on September 11, 2026. The filing also describes anti-takeover provisions under Delaware law and the company’s charter and bylaws.